Method for detecting illegally added pyrimidinone benzene compound in food and application
Through the liquid chromatography tandem mass spectrometry detection method, the problem of detecting illicit addition of pyrimidinone benzene compounds in food was solved, rapid qualitative and quantitative analysis was achieved, the risk of missed detection was reduced, and regulatory illegal addition was supported.
Patent Information
- Application Number
- CN202411260911.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-10
- Publication Date
- 2024-11-05
AI Technical Summary
Existing inspection standards cannot effectively detect pyrimidinone benzene compounds added illegally in food, making it difficult to regulate and combat illegal additions.
The liquid chromatography tandem mass spectrometry detection method was used to calculate pyrimidone by mixing the sample to be tested with methanol and sonicating and solid-liquid separation, using C8 chromatography column and electrospray ion source for gradient elution and negative ion mode detection, combined with standard curve analysis concentration of polybenzene compound.
Rapid qualitative and quantitative detection of illegal addition of pyrimidinonebenzene compounds in foods has been achieved, reducing the risk of missed detection and providing technical support to combat illegal addition.
Smart Images

Figure CN118897041A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of chemical substance detection, and in particular to a method and application for detecting pyrimidinone benzene compounds illegally added in food. Background Art
[0002] Phosphodiesterase 5 (PDE-5) inhibitors represented by sildenafil, tadalafil and vardenafil are widely used to treat erectile dysfunction (ED). Due to their huge market demand, the illegal addition of such drugs and new structural analogs to health foods and functional foods has been rampant. In order to evade the detection of regulatory authorities, the addition of new PDE-5 inhibitor analogs has become more and more common in recent years. The dosage of such PDE-5 analogs is uncontrolled and the toxicity is unknown, which will harm the health of consumers. We should pay attention to the illegal addition of these new analogs.
[0003] This type of health food or functional food often has the effects of strengthening sexual function, relieving physical fatigue, and enhancing immunity. It is made into oral solutions, tablets or capsules and other easy-to-take oral food forms. It is sold at a high price and has a large market share. However, its sales channels are hidden and difficult to regulate.
[0004] In order to curb such illegal additives, the State Drug Administration, the State Food and Drug Administration and the relevant departments of the State Administration for Market Regulation have successively promulgated inspection project approval documents (2008016, 2009030, BJS201805) and other inspection standards. Through thin layer chromatography, high performance liquid chromatography and mass spectrometry and other detection equipment, 90 kinds of aphrodisiac illegal additives can be detected. However, as far as the current illegal addition situation is concerned, the existing inspection standards have not met the actual regulatory needs. Pyrimidinone benzene structure compounds are new PDE-5 inhibitors, which are expected to be used for the treatment of male erectile dysfunction, but the detection method of illegally adding pyrimidinone benzene structure compounds in health foods and functional foods has not been reported, based on which the present invention is proposed. Summary of the invention
[0005] The purpose of the present invention is to provide a method and application for detecting pyrimidinone benzene compounds illegally added into food.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides a method for detecting illegally added pyrimidinone benzene compounds in food, comprising the following steps:
[0008] (1) mixing a sample to be tested with methanol to obtain a mixture, ultrasonically treating the mixture for 5 to 30 minutes, separating the solid from the liquid, taking the supernatant, filtering the supernatant, and taking the filtrate to obtain a solution to be tested;
[0009] (2) subjecting the test solution to liquid chromatography-tandem mass spectrometry detection;
[0010] The chromatographic conditions are as follows: C8 chromatographic column, column temperature of 25-40°C; flow rate of 0.2-0.4 mL / min; injection volume of 1-5 μL; mobile phase A is 0.05-0.12% ammonia solution, mobile phase B is methanol; gradient elution program is: 0-2 min, 28%-95% mobile phase B; 2-5 min, 95% mobile phase B; 5-6 min, 95%-28% mobile phase B; 6-9 min, 28% mobile phase B;
[0011] The mass spectrometry conditions were as follows: ion source: electrospray ion source; detection mode: multiple reaction ion monitoring mode; scanning mode: negative ion mode; nebulizing gas flow rate: 2.5-3.5 L / min; heating gas flow rate: 8-12 L / min; drying gas flow rate: 8-12 L / min; interface temperature: 280-350°C; desolvation temperature: 230-280°C; heating block temperature: 390-410°C; ion source voltage: -3.0--4.0 KV;
[0012] (3) qualitative analysis by comparing the retention time of each component of the chromatographic peak of the test solution and the deviation of the relative abundance ratio of the selected monitoring ion pair between the standard solution of the pyrimidinonebenzene compound of equivalent concentration and the test solution; obtaining the corresponding standard curve by analyzing the standard solutions of the pyrimidinonebenzene compound of different concentrations, substituting the detection results of the test solution by liquid chromatography-tandem mass spectrometry into the standard curve, and obtaining the concentration of the pyrimidinonebenzene compound in the test solution; substituting the concentration of the pyrimidinonebenzene compound into the calculation formula, and calculating the content of the pyrimidinonebenzene compound in the test sample.
[0013] Preferably, the pyrimidinone benzene compound is N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide and / or N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide.
[0014] Preferably, the mass volume ratio of the sample to be tested and methanol is 1 g: 10-60 mL.
[0015] Preferably, the temperature of the ultrasonic treatment in step (1) is 20-40° C., the frequency of the ultrasonic treatment is 25-50 KHz, and the power of the ultrasonic treatment is 159-250 W.
[0016] Preferably, the solid-liquid separation method in step (1) is centrifugation;
[0017] The centrifugal speed is 7000-9000 rpm, and the centrifugal time is 5-10 minutes.
[0018] Preferably, the filtering method in step (1) is membrane filtration; the pore size of the membrane is 0.2 to 0.25 μm.
[0019] Preferably, the mass spectrometry conditions in step (2) further include the setting of quantitative ion and qualitative ion parameters;
[0020] The quantitative ion for detecting N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholinoacetamide is: 427.20>284.10, and the qualitative ion is: 427.20>385.30;
[0021] When detecting N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholinoacetyl, the quantitative ion was: 413.15>270.10, and the qualitative ion was: 413.15>371.30.
[0022] Preferably, the calculation formula in step (3) is:
[0023]
[0024] Wherein: X represents the content of pyrimidinone benzene compound in the sample to be tested (mg / kg);
[0025] c represents the concentration of pyrimidinone benzene compound in the test solution (ng / mL);
[0026] v represents the final volume of the solution to be tested (mL);
[0027] m represents the weight of the sample to be tested (g);
[0028] k represents the dilution factor.
[0029] The present invention also provides application of the method in detecting illegally added pyrimidinone benzene compounds in food.
[0030] Preferably, the food is a functional food or a health food;
[0031] The functional food or health food is a food having one or more functions of tonifying the kidney, strengthening yang, resisting fatigue, relieving physical strength and improving sexual function;
[0032] The dosage form of the functional food or health food includes one or more of tablets, capsules, oral liquids, soft capsules, health wines, functional beverages, protein powders, granules and compressed candies;
[0033] The pyrimidinone benzene compound is N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide and / or N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide.
[0034] The present invention provides a method and application for detecting pyrimidinone benzene compounds illegally added into food. The detection method of the present invention comprises the following steps: (1) mixing a sample to be tested with methanol to obtain a mixture, ultrasonically treating the mixture for 5 to 30 minutes, separating the solid from the liquid, taking the supernatant, filtering the supernatant, taking the filtrate, and obtaining a solution to be tested; (2) subjecting the solution to be tested to liquid chromatography-tandem mass spectrometry detection; the chromatographic conditions are as follows: C8 chromatographic column, column temperature of 25 to 40° C.; flow rate of 0.2 to 0.4 mL / min; injection volume of 1 to 5 μL; mobile phase A is 0.05 to 0.12% ammonia aqueous solution, and mobile phase B is methanol; the gradient elution program is: 0 to 2 minutes, 28% to 95% mobile phase B; 2 to 5 minutes, 95% mobile phase B; 5 to 6 minutes, 95% to 28% mobile phase B; 6 to 9 minutes, 28% mobile phase B; the mass spectrometry conditions are as follows: the ion source is: electrospray ion source; the detection mode is: multiple reaction ion monitoring mode; the scanning mode is: Negative ion mode; nebulizing gas flow rate: 2.5-3.5 L / min; heating gas flow rate: 8-12 L / min; drying gas flow rate: 8-12 L / min; interface temperature: 280-350°C; desolvation temperature: 230-280°C; heating block temperature: 390-410°C; ion source voltage: -3.0--4.0 KV; (3) qualitative analysis by comparing the retention time of each component of the chromatographic peak of the test solution and the relative abundance ratio of the selected monitoring ion pairs of the standard solution of the pyrimidinonebenzene compound of equivalent concentration; by analyzing the standard solutions of the pyrimidinonebenzene compound of different concentrations, the corresponding standard curve is obtained, the test results of the liquid chromatography-tandem mass spectrometry of the test solution are substituted into the standard curve, and the concentration of the pyrimidinonebenzene compound in the test solution is obtained, and the concentration of the pyrimidinonebenzene compound is substituted into the calculation formula to calculate the content of the pyrimidinonebenzene compound in the test sample. According to the method of the present invention, N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide and / or N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide illegally added into health food or functional food can be rapidly and qualitatively and quantitatively detected. During the detection process, the sample to be tested only needs to be subjected to simple ultrasonic treatment and centrifugation before sampling. By optimizing the chromatographic conditions and mass spectrometry conditions during the detection process, it can be accurately determined whether the sample to be tested contains illegally added N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide and N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide, and their contents can be quantitatively detected.
[0035] The method of the present invention is suitable for detecting N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide and N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide illegally added in functional foods or health foods with the effects of tonifying the kidney, strengthening yang, resisting fatigue, relieving physical strength, and enhancing or improving sexual function, etc., supplements the gaps in existing inspection standards and methods reported in literature, reduces the risk of missed detection, and is expected to provide technical support for combating illegal additions. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 This is the quantitative ion chromatogram of compound JM06 on the C8 column (retention time 3.4 min);
[0037] Figure 2 This is the quantitative ion chromatogram of compound JM06A on the C8 column (retention time 3.2 min);
[0038] Figure 3 This is the quantitative ion chromatogram of compound JM06 on C18 column (retention time 4.4min);
[0039] Figure 4 This is the quantitative ion chromatogram of compound JM06A on the C18 column (retention time 4.3 min);
[0040] Figure 5 This is the quantitative ion chromatogram of compound JM06 on the T3 column (retention time 4.4 min);
[0041] Figure 6 This is the ion chromatogram of compound JM06A on T3 column (retention time 4.3min);
[0042] Figure 7 Qualitative and quantitative ion chromatograms of compounds JM06 and JM06A (from top to bottom they are quantitative ion chromatogram of JM06, qualitative ion chromatogram of JM06, quantitative ion chromatogram of JM06A and qualitative ion chromatogram of JM06A). DETAILED DESCRIPTION
[0043] In the present invention, N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholinoacetamide is referred to as JM06; N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholinoacetamide is referred to as JM06A.
[0044] The solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be understood as limiting the protection scope of the present invention.
[0045] In the examples of the present invention, JM06 is used to represent N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide; JM06A is used to represent N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide.
[0046] The instruments and reagents used in the embodiments of the present invention include: Ultimate 3000DGLC high performance liquid chromatograph (Thermo Fisher, USA); Q-Exactive liquid chromatograph tandem high resolution mass spectrometer (Thermo Fisher, USA); LCMS-8050 liquid chromatograph mass spectrometer (Shimadzu, Japan); DV215CD electronic balance (Mettler, USA); Quintix224-1CN electronic balance (OHAUS, USA); THC-108 ultrasonic extractor (Jining Tianhua Ultrasonic Electronic Instrument Co., Ltd.); PURELAB Flex ultrapure water system (ELGA, UK); 3K15 refrigerated centrifuge (Sigma, Germany); Thermo syncronil C18 (2.1×100 mm, 2.7 μm) chromatographic column; CORTECS T3 chromatographic column (2.0 mm×100 mm, 2.7 μm) (Waters Corporation, USA); Shim-packXR-C8 chromatographic column (2.1 mm×100 mm, 2.2 μm) (Shimadzu Corporation, Japan).
[0047] Reagents: acetonitrile (chromatographic grade, Merck, Germany); methanol (chromatographic grade, Merck, Germany); formic acid (chromatographic grade, TGI, Japan); ammonia (chromatographic grade, Sinopharm Chemical Reagent Co., Ltd.).
[0048] Standard product: JM06 (batch number: 20240401, purity: 96.17%, purchased from Anhui Aobo Biotechnology Co., Ltd.); JM06A (batch number: 20240401, purity: 97.83%, purchased from Anhui Aobo Biotechnology Co., Ltd.).
[0049] Samples to be tested: American ginseng lozenges, glucosamine sulfate chondroitin sodium wolfberry capsules, oyster soybean peptide carnitine oral liquid, ginseng vinegar soft capsules, China Jinjiu, Red Bull vitamin taurine drink, protein powder, broken wall Ganoderma lucidum spore powder, astragalus amino acid oral liquid, multi-dimensional Ganoderma lucidum amino acid tablets, coenzyme Q10 vitamin E soft capsules, coenzyme Q10 granules, etc. are from online shopping products and samples randomly inspected by the Institute of Drug Inspection Technology of Shanxi Provincial Inspection and Testing Center from 2020 to 2023.
[0050] Example 1
[0051] Optimization of chromatographic conditions
[0052] Optimize the type and elution conditions of the mobile phase: 0.1% formic acid aqueous solution-acetonitrile, 0.1% formic acid aqueous solution-methanol, water-acetonitrile, water-methanol, 5mmol / L ammonium formate aqueous solution-acetonitrile, 5mmol / L ammonium formate aqueous solution-methanol, 0.1% ammonia aqueous solution-acetonitrile, 0.1% ammonia aqueous solution-methanol as mobile phase, investigate the peak shape and sensitivity of JM06 and JM06A compounds. The results are shown in Table 1. The study found that: under the same aqueous phase conditions, when the organic phase is methanol, the solvent effect of the two compounds is small and the peak area is greater than when the organic phase is acetonitrile, so methanol is selected as the organic phase solvent; with methanol as the organic phase, the four aqueous phase conditions are compared, and the peak shape of 0.1% formic acid water is the best, the compound peak area is the smallest, the peak shape of 0.1% ammonia aqueous solution-methanol system is in the middle, and the compound peak area is the largest, so it is selected as the mobile phase system.
[0053] Table 1 Results of system suitability investigation of two compounds under different mobile phase conditions
[0054]
[0055] The separation effects of C8, C18 and T3 columns on JM06 and JM06A were investigated using gradient elution mode. Figures 1 to 6 shown.
[0056] The results showed that there was little difference in the peak shape and separation effect of the compounds under the three chromatographic conditions. The C8 column produced the earliest peak, so the C8 column was finally selected as the chromatographic column for this method.
[0057] The final optimized chromatographic conditions were: using a C8 chromatographic column, column temperature 25-40°C; flow rate 0.2-0.4mL / min; injection volume 1-5μL; mobile phase A was 0.05-0.12% ammonia solution, mobile phase B was methanol, gradient elution: 0-2min, 28%-95% mobile phase B; 2-5min, 95% mobile phase B; 5-6min, 95%-28% mobile phase B; 6-9min, 28% mobile phase B.
[0058] The optimal conditions were: C8 chromatographic column, column temperature 35°C; flow rate 0.3mL / min; injection volume 1μL; mobile phase A was 0.1% ammonia solution, mobile phase B was methanol, gradient elution: 0-2min, 28%-95% mobile phase B; 2-5min, 95% mobile phase B; 5-6min, 95%-28% mobile phase B; 6-9min, 28% mobile phase B.
[0059] Example 2
[0060] Optimization of mass spectrometry conditions
[0061] Preparation of standard stock solution: Accurately weigh 10 mg of JM06 and JM06A standards, place them in 10 mL volumetric flasks respectively, dissolve and dilute to the scale with methanol, shake well to make a single-label standard stock solution with a concentration of 1 mg / mL, store at -20℃, and the validity period is 3 months.
[0062] Preparation of mixed standard intermediate solution: Accurately pipette 0.1 mL of each of the above single-label standard stock solutions into a 100 mL volumetric flask, dilute to the mark with methanol, and shake well to obtain a 1 μg / mL mixed standard intermediate solution.
[0063] Preparation of mixed standard working solution: Accurately pipette 0.5 mL of mixed standard intermediate solution into a 10 mL volumetric flask, dilute to the mark with methanol, and shake well to obtain 50 ng / mL mixed standard working solution.
[0064] The mixed standard working solution was subjected to product ion scanning. The results showed that under the positive ion mode (ESI+), both compounds had only two fragment ions, m / z100 and m / z70. The m / z70 fragment had low intensity and a small m / z value, which was prone to interference and the possibility of false positives. Therefore, the negative ion scanning mode (ESI-) was selected and the collision energy and other parameters of the fragments were optimized. The optimized mass spectrometry parameters are shown in Table 2.
[0065] Table 2 Optimized mass spectrometry parameters
[0066]
[0067]
[0068] Note: The ions marked with * are quantitative ions.
[0069] The final mass spectrometry conditions were determined as follows:
[0070] Ion source: electrospray ion source (ESI); detection mode: multiple reaction ion monitoring mode (MRM); scanning mode: negative ion mode; nebulizer gas flow rate: 2.5-3.5 L / min; heating gas flow rate: 8-12 L / min; drying gas flow rate: 8-12 L / min; interface temperature: 280-350°C; desolvation (DL) temperature: 230-280°C; heating block temperature: 390-410°C; ion source voltage: -3.0--4.0 KV;
[0071] The optimal conditions are: ion source: electrospray ion source (ESI); detection mode: multiple reaction ion monitoring mode (MRM); scanning mode: negative ion mode; nebulizing gas flow rate: 3.0L / min; heating gas flow rate: 10L / min; drying gas flow rate: 10L / min; interface temperature: 300℃; DL temperature: 250℃; heating block temperature: 400℃; ion source voltage: -3.5KV.
[0072] The chromatographic and mass spectrometric conditions of the following examples were all tested according to the optimal conditions of Examples 1-2.
[0073] Example 3
[0074] Study of matrix effects
[0075] According to the types of health foods and functional foods that are common in the market and have the effects of strengthening yang, relieving physical fatigue and helping to enhance immunity, three common dosage forms of tablets, capsules and oral liquids were selected for method development. The specific experimental samples were: American ginseng lozenges, glucosamine sulfate chondroitin sodium wolfberry capsules, and oyster soybean peptide carnitine oral liquid (all three were negative samples) for research.
[0076] Sample preparation: For solid samples, take no less than 20 tablets, mix and grind; for capsules, take no less than 20 capsules, mix and grind the contents; for liquid samples, take no less than 5 bottles and mix.
[0077] Extraction of the sample to be tested: Accurately weigh 1g of the sample to be tested into a 50mL volumetric flask, add 35mL of methanol, and ultrasonically extract for 15min at 30℃, with an ultrasonic frequency of 33KHz and a power of 250W. Cool to room temperature, add methanol to the scale, shake well, transfer to a 50mL centrifuge tube, centrifuge at 8000rpm for 5min, take the supernatant, filter through a 0.22μm organic filter membrane, and take the filtrate as the solution to be tested. When measuring, appropriately dilute with methanol to within the range of the standard curve according to the actual situation.
[0078] Mixed standard series working solution: Take the 1 μg / mL mixed standard intermediate solution in Example 2, accurately pipette appropriate volumes into 10 mL volumetric flasks, dilute to the mark with methanol, and obtain JM06 and JM06A mixed standard series working solutions with concentrations of 20, 40, 80, 100, 160, and 200 ng / mL, respectively.
[0079] Preparation of matrix standard curves: According to the method for extracting solid samples to be tested, dilute the three negative samples to the same concentration as the mixed standard series working solution to obtain three negative matrix extracts.
[0080] The strength of the matrix effect was determined by comparing the difference in the slope of the standard curve between the mixed standard series working solution and the negative matrix extract, as shown in Table 3.
[0081] The calculation formula is as follows:
[0082] Matrix effect = [(slope of matrix-matched standard curve / slope of solvent standard curve) - 1] x 100%.
[0083] Table 3 Linear range, limit of quantification, limit of detection and matrix effect
[0084]
[0085] As shown in Table 3, the matrix effects of JM06 and JM06A in oral solution were less than ±20%, which was a weak matrix effect. The matrix effects in tablets and capsules were ≥ ±50%, which was a strong matrix effect. After comprehensive consideration, the negative matrix extract standard curve was selected for quantitative analysis of JM06 and JM06A to reduce the influence of the matrix effect.
[0086] The basis for qualitative judgment is: if the retention time of the chromatographic peak of the sample solution to be tested and the standard solution of a certain compound is consistent (within the range of variation of ±2.5%), and the deviation of the relative abundance ratio of the selected monitoring ion pairs between the sample solution to be tested and the standard solution of equivalent concentration does not exceed the range specified in Table 4, then it can be determined that the sample to be tested contains the compound.
[0087] Table 4 Maximum allowable deviation of relative ion abundance
[0088] Relative ion abundance (%) k>50% 50%≥k>20% 20%≥k>10% k≤10% Maximum allowable deviation (%) ±20 ±25 ±30 ±50
[0089] The quantitative calculation method is:
[0090] Substitute the test results of the liquid chromatography-tandem mass spectrometry of the test solution into the corresponding standard curve to obtain the concentration of the pyrimidinone benzene compound in the test solution, and substitute the concentration of the pyrimidinone benzene compound into the calculation formula to calculate the content of the pyrimidinone benzene compound in the test sample.
[0091] The calculation formula is:
[0092]
[0093] Wherein: X represents the content of pyrimidinone benzene compound in the sample to be tested (mg / kg);
[0094] c represents the concentration of pyrimidinone benzene compound in the test solution (ng / mL);
[0095] v represents the final volume of the solution to be tested (mL);
[0096] m represents the weight of the sample to be tested (g);
[0097] k represents the dilution factor.
[0098] Example 4
[0099] Methodological research
[0100] Exclusive
[0101] The negative matrix extracts of American ginseng tablets, glucosamine sulfate chondroitin sodium wolfberry capsules, and oyster soybean peptide carnitine oral liquid prepared in Example 3 were taken respectively, and the negative matrix extracts were tested on the machine. No JM06 or JM06A was detected in the three negative matrix extracts. Another portion of each of the three negative matrix extracts was weighed, and 0.20 mL of the mixed standard intermediate solution prepared in Example 2 was added to each of them, and quantitative analysis was performed as a control sample. The results showed that JM06 and JM06A chemical substances could be detected, indicating that the blank matrix did not interfere with the detection of the above-mentioned JM06 and JM06A compounds.
[0102] Linear range, limit of quantitation and limit of detection
[0103] According to the chromatographic conditions determined in Example 1 and the mass spectrometry conditions determined in Example 2, the matrix standard curves of the three negative matrix extracts were injected and measured, and the mass concentration of the analyte (X, ng / mL) was used as the abscissa and the corresponding peak area (Y) was used as the ordinate to draw the standard curve. As shown in Table 3. The results show that JM06 and JM06A have a good linear relationship in the concentration range of 20 to 200 ng / mL, and the R values are all greater than 0.99.
[0104] Take the prepared American ginseng tablets (tablets), glucosamine sulfate chondroitin sodium wolfberry capsules (capsules), oyster soybean peptide carnitine oral liquid samples (oral liquid), accurately weigh 1g in a 50mL volumetric flask, add an appropriate volume of the mixed standard intermediate solution prepared in Example 2, add 35mL of methanol, ultrasonic extraction for 15min, cool to room temperature, add methanol to the scale, shake well, transfer to a 50mL centrifuge tube, centrifuge at 8000rpm for 5min, take the supernatant, filter through a 0.22μm organic filter membrane, take the filtrate, and test it as a detection limit and quantitative limit solution. When the signal-to-noise ratio of the qualitative ion pair chromatographic peak of each analyte is measured to be 10, the quantitative limit of this method is calculated. When the signal-to-noise ratio is 3, the detection limit of this method is calculated. The quantitative limit of JM06 and JM06A is 1.0mg / kg, and the detection limit is 0.5mg / kg. The results are shown in Table 3.
[0105] Spike recovery and precision
[0106] The specificity experiment showed that the three negative matrix extracts of American ginseng tablets, glucosamine sulfate chondroitin sodium wolfberry capsules, and oyster soybean peptide carnitine oral solution samples did not contain JM06 and JM06A compounds.
[0107] The spike recovery experiment was carried out at three concentrations: low, medium and high. Six samples were used at each concentration level. The recovery rate was calculated to examine its accuracy. The recovery rate RSD (%) value was used to examine its precision. 18 samples of three kinds of samples, namely American ginseng tablets, glucosamine sulfate chondroitin sodium wolfberry capsules and oyster soybean peptide carnitine negative matrix, were accurately weighed; JM06 and JM06A compounds were spiked at concentration levels equivalent to 1.0, 2.0 and 10.0 mg / kg in the samples. Sample extraction and analysis were performed according to the method of Example 3. The recovery rate and RSD value were calculated and the results are shown in Table 5.
[0108] Table 5 Recovery and relative standard deviation of compounds JM06 and JM06A (n=6)
[0109]
[0110] According to GB / T 27404-2008 "Laboratory Quality Control Specifications for Physical and Chemical Testing of Foods", the recovery range is 80% to 110% when the content of the measured component is 0.1-1.0 mg / kg, and the recovery range is 90% to 110% when the content is 1-100 mg / kg. In the three matrices, the recovery results of compounds JM06 and JM06A are 91.3% to 105.4%, which are all within the standard allowable range; the RSD values of compounds JM06 and JM06A in the three matrices are 0.61% to 3.6%, which meets the standard requirements, indicating that the accuracy and precision of this method are good and it is suitable for the determination of JM06 and JM06A in health foods with different matrices.
[0111] Example 5
[0112] According to the optimal chromatographic conditions determined in Example 1 and the best mass spectrometry conditions determined in Example 2, the 50 ng / mL mixed standard working solution prepared in Example 2 was analyzed and tested using a C8 chromatographic column. The spectrum results are shown in FIG. Figure 7 shown.
[0113] Example 6
[0114] Twelve kinds of health foods on the market that have the effects of strengthening yang, relieving physical fatigue and helping to enhance immunity (American ginseng tablets, glucosamine sulfate chondroitin sodium wolfberry capsules, oyster soybean peptide carnitine oral liquid, ginseng and antler vinegar soft capsules, China Jingjiu, Red Bull vitamin taurine beverage, protein powder, broken wall ganoderma lucidum spore powder, astragalus amino acid oral liquid, multi-dimensional ganoderma lucidum amino acid tablets, coenzyme Q10 vitamin E soft capsules, coenzyme Q10 granules) were tested according to the preferred conditions of Examples 1 to 5. The results showed that no chemical substances JM06 and JM06A were detected. The above two chemical substances were detected in the deer whip peptide tablet candy with aphrodisiac effect sold on the network platform.
[0115] As can be seen from the above embodiments, the present invention provides a method and application for detecting illegally added pyrimidinone benzene compounds in food. According to the method of the present invention, the content of N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide and / or N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide illegally added in health food or functional food can be quickly detected qualitatively and quantitatively. During the detection process, the sample to be tested only needs to be subjected to simple ultrasonic treatment and centrifugation before sampling. By optimizing the chromatographic conditions and mass spectrometry conditions during the detection process, it can be accurately determined whether the sample to be tested contains illegally added N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide and / or N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide, and its content can be quantitatively detected. The method of the present invention is suitable for detecting the illegal addition of N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide and / or N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide in functional foods or health foods with the effects of tonifying the kidney, strengthening yang, resisting fatigue, relieving physical strength, and enhancing or improving sexual function, etc., supplements the gaps in existing inspection standards and methods reported in literature, reduces the risk of missed detection, and is expected to provide technical support for combating illegal additions.
[0116] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for detecting illegally added pyrimidinone benzene compounds in food, characterized in that: The steps include: (1) Mixing a sample to be tested with methanol to obtain a mixture, ultrasonically treating the mixture for 5 to 30 minutes, separating the solid and liquid, collecting the supernatant, filtering the supernatant, and collecting the filtrate to obtain a solution to be tested; (2) subjecting the test solution to liquid chromatography tandem mass spectrometry detection; Chromatographic conditions were as follows: C8 column, column temperature 25-40°C; flow rate 0.2-0.4 mL / min; injection volume 1-5 μL; mobile phase A was 0.05-0.12% ammonia solution, mobile phase B was methanol; gradient elution program was: 0-2 min, 28%-95% mobile phase B; 2-5 min, 95% mobile phase B; 5-6 min, 95%-28% mobile phase B; 6-9 min, 28% mobile phase B; The mass spectrometry conditions were as follows: ion source: electrospray ionization source; detection mode: multiple reaction ion monitoring mode; scanning mode: negative ion mode; nebulizing gas flow rate: 2.5-3.5 L / min; heating gas flow rate: 8-12 L / min; drying gas flow rate: 8-12 L / min; interface temperature: 280-350°C; desolvation temperature: 230-280°C; heating block temperature: 390-410°C; ion source voltage: -3.0--4.0 kV; (3) Qualitative analysis is performed by analyzing and comparing the retention time of each component of the chromatographic peak of the test solution and the deviation of the relative abundance ratio of the selected monitoring ion pair of the pyrimidinonebenzene compound standard solution of equivalent concentration; by analyzing the pyrimidinonebenzene compound standard solution of different concentrations, the corresponding standard curve is obtained, and the detection results of the test solution by liquid chromatography-tandem mass spectrometry are substituted into the standard curve to obtain the concentration of the pyrimidinonebenzene compound in the test solution, and the concentration of the pyrimidinonebenzene compound is substituted into the calculation formula to calculate the content of the pyrimidinonebenzene compound in the test sample.
2. The method according to claim 1, characterized in that The pyrimidinone benzene compound is N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide and / or N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide.
3. The method according to claim 2, characterized in that The mass volume ratio of the sample to be tested and methanol is 1 g: 10-60 mL.
4. The method according to claim 3, characterized in that The temperature of the ultrasonic treatment in step (1) is 20-40° C., the frequency of the ultrasonic treatment is 25-50 KHz, and the power of the ultrasonic treatment is 159-250 W.
5. The method according to claim 4, characterized in that The solid-liquid separation method in step (1) is centrifugation; The centrifugal speed is 7000-9000 rpm, and the centrifugal time is 5-10 minutes.
6. The method according to claim 5, characterized in that The filtration method in step (1) is membrane filtration; the pore size of the membrane is 0.2 to 0.25 μm.
7. The method according to claim 6, characterized in that The mass spectrometry conditions in step (2) also include the setting of quantitative ion and qualitative ion parameters; When detecting N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholinoacetamide, the quantitative ion is: 427.20>284.10, and the qualitative ion is: 427.20>385.30; When detecting N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholinoacetyl, the quantitative ion was: 413.15>270.10, and the qualitative ion was: 413.15>371.
30.
8. The method according to claim 7, characterized in that The calculation formula in step (3) is: Wherein: X represents the content of pyrimidinone benzene compound in the sample to be tested (mg / kg); c represents the concentration of pyrimidinone benzene compound in the test solution (ng / mL); v represents the final volume of the test solution (mL); m represents the weight of the sample to be tested (g); k represents the dilution factor.
9. Use of the method according to any one of claims 1 to 8 in detecting illegally added pyrimidinone benzene compounds in food.
10. The use according to claim 9, characterized in that The food is a functional food or a health food; The functional food or health food is a food having one or more effects of tonifying the kidney, strengthening yang, resisting fatigue, relieving physical strength and improving sexual function; The dosage form of the functional food or health food includes one or more of tablets, capsules, oral liquids, soft capsules, health wines, functional drinks, protein powders, granules and compressed candies; The pyrimidinone benzene compound is N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide and / or N-(3-(5-ethyl-4-methyl-6-oxo-1,6-dihydropyrimidine-2-)-4-n-propoxyphenyl)-2-morpholineacetamide.
